| INTRODUCTION
Hepatitis C virus (HCV) infection is, at present, one of the most frequent causes of cirrhosis in the western world, representing both a social and substantial health burden. 1 Until recently, the standard of care for treatment of HCV infection was the combination of pegylated interferon alpha and ribavirin, which obtained virus clearance in a substantial fraction of patients, but at a high cost in terms of side effects. The advent of the new direct-acting antivirals, by targeting the hepatitis C viral proteins including NS3/4A, NS5A, and NS5B, changed dramatically the treatment of HCV infection reaching a high rate of HCV eradication with a low frequency of side effects.
Pro-inflammatory status and pro-fibrotic cytokines play an important role in the pathogenesis of liver damage during HCV infection, although the mechanisms involved are not completely clarified. 2 Several authors have reported that chronic inflammation and liver fibrosis in chronic HCV infection, are associated with microbial translocation (MT), from the gut lumen to the systemic circulation. [3] [4] [5] Indeed, lipopolysaccharide (LPS), which is a component of the outer layer of Gram-negative bacteria, is able to stimulate liver resident
Kupffer and hepatic stellate cells, thereby contributing to the development of liver fibrosis. 6 Several plasma proteins have been validated as biomarkers of microbial translocation. Among these, lipopolysaccharide binding protein (LBP) and soluble CD14 (sCD14), have been used to measure the degree of microbial translocation in the peripheral blood. [7] [8] [9] [10] Intestinal fatty acid-binding protein (I-FABP), reflecting enterocyte damage, is an additional biomarker strictly related to microbial translocation. 11, 12 Microbial translocation occurs as a consequence of disruption of the intestinal barrier integrity. This condition is associated with a range of diseases such as intestinal ischemia, inflammatory bowel disease, graft-versus-host disease, and chronic viral infections including human immunodeficiency virus (HIV) and hepatitis C virus. 13, 14 Microbial translocation products are considered a driving force of systemic immune activation in which increase of CD38+ and HLADR+ expression is one of the main feature. Changes in microbial translocation markers in subjects with HCV infection treated with pegylated interferon and ribavirin have been reported in two studies. 15, 16 Biomarkers of microbial translocation were found to be associated with the treatment outcome; however, in both studies, the results could have been partly influenced by the presence of pegylated interferon alpha in the treatment regimen, which may interfere with plasma levels of sCD14 by activating monocytes.
We therefore, conducted an observational study aiming at evaluating the modifications of microbial translocation and of T cells activation marker, in HCV-infected patients treated with direct-acting antiviral regimens.
| MATERIALS AND METHODS
Two groups of patients with chronic HCV infection, undergoing direct-acting antiviral therapy, were included in the study. The first group included patients with HCV infection and advanced fibrosis (F3-F4 according to Metavir) (Group ≥F3). The second group included patients with HCV recurrence after liver transplantation (LT) and fibrosis ≥ F2 according to Metavir (Group LT + ≥F2). Exclusion criteria in both groups were HIV co-infection, inflammatory bowel disease or other chronic intestinal diseases, alcohol abuse in the last 3 months and other concomitant causes of liver disease in addition to HCV infection.
A group of 11 healthy subjects were enrolled as controls for basal microbial translocation surrogate biomarkers.
The following antiviral treatments were administered: inhibitor of non-structural protein 5B (NS5B) sofosbuvir together with ribavirin for 24 weeks; sofosbuvir + inhibitor of NS4 (simeprivir) for 12 weeks in association with ribavirin (when indicated and in absence of contraindications); sofosbuvir + inhibitor of NS5A (ledipasvir or daclatasvir) for 12 or 24 weeks with or without ribavirin.
The choice of treatment for each patient was based on the current guidelines according to the genotype, the characteristics of patients and the availability of drugs in our country/region at that moment.
Chronic HCV infection was defined as persistence of HCV RNA in serum 6 months after infection. 17 Sustained virological response Non-invasive assessment of liver fibrosis was performed at T0
and T3 through Fibroscan ® (Echosens, Paris). At least 10 valid measurements, a 60% success rate, an interquartile range of less than 30% of the median elasticity, were required for eligibility. 18 The study was approved by the Ethical Committee of La 
| Flow cytometry analysis
Multi-color flow cytometry analysis was performed on whole blood. 
| Statistical analysis
Statistical analyses and graphical presentation were done using SPSS 
| RESULTS

| Study population
Forty-five subjects with chronic HCV hepatitis were included in the study: 32 patients in Group ≥F3 and 13 patients in Group LT + ≥F2. All patients in the latter group were receiving immunosuppressive therapy to prevent graft rejection. The baseline characteristics of the patients are shown in Table 1 . Eleven healthy subjects (73% males, median age 48 ± 5.4 years) were utilised as control group.
Severe fibrosis was almost universal in Group ≥F3 (F4 91%) but less frequent in the transplanted patients at the time of treatment (F4 38% P < 0.05). Due to the characteristics of patients (including genotype) and drugs available at the time of treatment, direct-acting antiviral regimens were different in the two groups: most of the patients in Group ≥F3 were treated with sofosbuvir + NS5A inhibitor (ledipasvir or daclatasvir) (53%), followed by those treated with sofosbuvir + simeprevir (38%) and with sofosbuvir alone (9%). On the other hand, patients of Group LT + ≥F2 were treated mostly with sofosbuvir alone (62%), followed by sofosbuvir + simeprevir (38%). Ribavirin was used in all transplanted patients and in 50% of Group ≥F3.
| Virological outcome
A sustained virological response at 12 weeks was obtained in thirty patients (94%) in Group ≥F3 and in eleven patients (85%) in Group LT + ≥F2. Modifications in liver function tests, viral load and (38) MELD score 9.0 (7-11.0) 9.0 (7.0-10.5) 0.400
Gastro-oesophageal varices, n (%) None 19 (59) 12 (92) 0.070
Values are expressed as medians (IQR) or percentages. HCV: hepatitis C virus; LT: liver transplantation; MELD: model for end stage liver disease; SVR: sustained virological response.
ultrasonography parameters before, during and after treatment are shown in Table 2 . An amelioration in transaminases, serum albumin levels, and liver stiffness was observed in both groups during and after treatment.
| Basal LBP, sCD14 and I-FABP in HCV patients and healthy controls
Baseline levels of markers of microbial translocation and enterocyte damage are reported in Figure 1 . In both groups, plasma levels of LBP, sCD14, and I-FABP were increased when compared to healthy subjects. Plasma values measured in this latter group were consistent with those reported for adult healthy population in the individual package inserts of the relevant ELISA assays.
Specifically, median sCD14 values at baseline in HCV patients of were significantly higher in comparison with healthy controls (1176.0 ng/mL, IQR: 1048.0-1358.0; P < 0.0001) with no differences between group ≥F3 and group LT + ≥F2 (1928.5 ng/mL, IQR:
1441.8-2321.5 vs 2117.5 ng/mL, IQR: 1814.5-2161.5 P = 0.430).
Baseline LBP level, on the other hand, were higher in Group LT + 173.0-374.0, P = 0.008). sCD14 levels in both groups significantly correlated with I-FABP (r = 0.342; P = 0.01) and LBP (r = 0.430; P = 0.001) ( Figure S1 ).
To better understand the clinical significance of our findings, we analysed potential correlations between baseline sCD14 levels and markers of hepatic necrosis, fibrosis, and liver protein synthesis. We found that sCD14 plasma levels were associated with the increase of glutamic-oxalacetic transaminase (r = 0.384, P = 0.009) and glu- 
| Changes of LBP, I-FABP, and sCD14 during direct-acting antiviral treatment
In group ≥F3, following the sharp decrease of viral load during the first month of treatment, plasma levels of sCD14 and LBP showed a rapid and significant decline. Three months after the end of the treatment sCD14 and LPB plasma levels remained significantly lower with respect to baseline (P = 0.016 and P = 0.04, respectively).
I-FABP plasma levels showed a minor non-significant decline during direct-acting antiviral treatment (Figure 3 ). 
Patients in group LT
| Factors associated with HCV relapse
Only four patients (two in each group), experienced HCV relapse after treatment. Age, gender, viral genotype, and viral load, type of treatment, baseline stiffness (kPa), baseline LBP and I-FABP levels were similar in patients reaching SVR 12 and in those with relapse.
On the other hand, we observed that in both groups, the sCD14 levels at baseline were significantly higher in the relapsers with respect to patients with SVR12 (2582.5 ng/mL vs 1777.5 ng/mL, P = 0.019). Nevertheless, the trend in sCD14 decrease during treatment was similar in patients with and without SVR. High levels of surrogate microbial translocation markers in HCV patients confirm the observation by other authors 3, 16, 20 who also suggested that microbial translocation may contribute to persistent inflammation and development of fibrosis in chronic HCV infection. 16 Even if the mechanism underlying the link between HCV infection and microbial translocation was beyond the purpose of our study, a possible explanation could be related to gut epithelial damage, as was observed in a study 21 conducted in HIV/HCV coinfected patients, in whom HIV is known to colonise enterocytes. However, I-FABP, which is a marker of enterocyte damage, 12 was not increased in our series, suggesting that the pathogenetic role of gut epithelial damage is unlikely in our patients. Portal hypertension, derived from liver fibrosis and portosystemic shunting, has also been claimed to cause an alteration of intestinal permeability mainly in cirrhotic patients 22 ; this could partially contribute to explain the increase in microbial translocation surrogate markers in our series of compensated advanced liver disease (Group ≥F3) with presence of oesophageal varices in 41% of patients.
Immunological impairment can also lead to a less efficient intestinal barrier and increased microbial translocation as is the case in other conditions of immunodeficiency. [23] [24] [25] This may be supported by the observation that liver transplanted patients (group LT + ≥F2), receiving chronic immunosuppressive therapy, showed higher levels of microbial translocation respect to group ≥F3, in the absence of portal hypertension in the majority of them. Indeed, in group LT + ≥F2, sCD14, as well as other surrogate biomarkers of microbial translocation, tended to be higher than in group ≥F3. This is consistent with previous reports that have shown a persistent status of immune activation, likely due to subclinical infections associated with lifelong immunosuppressive therapy, in liver transplant patients. 26, 27 Increased levels of LBP have also been reported during acute and chronic rejections, 25 our patients, however, had no signs of rejection.
In both groups, the levels of sCD14 were elevated when compared to healthy subjects and correlated with transaminases levels.
Similar findings have been described in a cohort of HCV patients by
Sandler et al 16 who also found a significant correlation between microbial translocation and the degree of liver fibrosis. Although these patients were rather similar to those in our cohort, we failed to find an association between microbial translocation surrogate markers and Metavir. Indeed, sCD14 and I-FABP levels were similar in patients with different degree of fibrosis. The different methods utilised for the assessment of liver fibrosis (liver biopsy vs Fibroscan)
could have also influenced the results.
Moreover, despite portal hypertension is known to cause an alteration of intestinal permeability, we failed to find this association in our study. This was probably due to the mild degree of portal hypertension in our series. In fact, as shown in Table 1 , none of our patients had experienced ascites and only 7 patients (15%) had varices ≥ F2. In the contest of compensated liver disease, it is likely that other mechanisms, such as hepatic inflammation, intestinal damage and alteration in immune system, could have been more relevant as a cause of microbial translocation. The rapid decline of microbial translocation surrogate markers after direct-acting antiviral treatment suggests that viral clearance may affect microbial translocation. This makes unlikely a relevant role of portal hypertension, mainly in group ≥F3, as the amelioration of portal hypertension, when reversible, is known to take longer than 3 months after eradication. 29 The evidence that direct-acting antiviral therapy, through HCV clearance, can modify the immune system is provided by studies about HCV-cryoglobulinemia vasculitis in which direct-acting antivirals effectively normalises many of the abnormalities in peripheral B-and T-lymphocytes homeostasis. 30 Specific restoration of proliferative CD8+ T-cell responses was observed, when lymphocytes were stimulated by HCV antigens, following HCV elimination by an interferon-free direct-acting antiviral regimens 31 and it has been reported that successful interferon-free therapy prevented interferon-mediated intrahepatic immune activation and resulted in normalisation of Natural Killer cell functions. 32, 33 T regulatory cells play an important role in HCV infection, both in the maintenance of chronicity by inhibiting anti-HCV immune responses and in attenuating the intrahepatic tissue-damaging response to infection. 34 Literature data exist also indicating that in chronic HCV infection colonic T regulatory cells are higher than in controls 35 and this finding may lead to alteration in the gut barrier and increased microbial translocation, potentially reversible after therapy.
In our study, after direct-acting antiviral treatment, we found a significant decline in markers of T-cell activation. A previous study also reported a decline of T-cells CD38+HLADR+ expression in chronic HCV patients, after interferon-free treatment. 36 The immunophenotypic analysis was performed only in Group ≥F3, since it is known that the chronic immunosuppressive therapy, as administered in patients in Group LT + ≥F2, could impact on the CD38 expression on T-cells. Indeed, it has been reported that CD38 expression on T-cells is under-expressed after anti-rejection therapy, and its determination has been proposed as assay to be used routinely to quantify the level of immunosuppression in clinical practice. 37 Overall, our results suggest that direct-acting antiviral treatment is associated to a reduction in inflammation and generalised immune activation. It can be speculated that, this will lead to a reduction in cirrhosis-related complications, including arterial vasodilatation, hyperdynamic circulation and bacterial infections. 38 Further studies, with longer follow up are needed to confirm this hypothesis.
As expected, the relapse rate was very low in our patient population, occurring only in 4 subjects (2 in Group ≥F3 and 2 in Group LT + ≥F2). Interestingly, these patients, independently from groups, showed baseline sCD14 levels significantly higher when compared PEG-interferon with or without ribavirin) was significantly associated with treatment failure. 16 Our study, to our knowledge, is one of the first studies where changes of microbial translocation markers during direct-acting antiviral treatment were evaluated in a population of liver transplanted patients with HCV infection recurrence. The study has, however, some limitations: first, the limited number of patients; second, we did not measure directly LPS plasma levels. However, measuring LPS concentration is a technically complex process that can be further complicated by its rapid clearance and by the presence of inhibitory plasma proteins. [39] [40] [41] In this view, LPS-binding protein (LBP), a protein with a relatively long half-life synthesised by the liver in response to bacteraemia, 42, 43 can be considered a reasonable surrogate biomarker for assessing LPS-induced inflammation in humans.
At the same time, as for many other acute phase proteins, the liver is directly responsible for LBP synthesis, 44 and the LBP upregulation may be compromised in case of an impaired capacity of the liver, 45 making the interpretation of results sometimes difficult. Moreover, it is important to underline that this study refers to first generation direct-acting antivirals.
In conclusion, our findings suggest that direct-acting antiviral therapy can significantly reduce plasma levels of microbial translocation biomarkers and proportion of activated T-cells in HCV patients with advanced fibrosis. These effects persist at 3 months after the end of therapy. Further studies, conducted in larger cohorts of patients, with longer follow up, will allow to understand the possible clinical consequences of the reduction/normalisation of systemic inflammation.
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